Interphase FISH analysis of PTEN in histologic sections shows genomic deletions in 68% of primary prostate cancer and 23% of high-grade prostatic intra-epithelial neoplasias.

[1]  H. Stoop,et al.  The PTEN gene in locally progressive prostate cancer is preferentially inactivated by bi‐allelic gene deletion , 2006, The Journal of pathology.

[2]  Yiling Lu,et al.  Enhancement of antitumor activity of the anti-EGF receptor monoclonal antibody cetuximab/C225 by perifosine in PTEN-deficient cancer cells , 2006, Oncogene.

[3]  W. Sellers,et al.  Akt-regulated pathways in prostate cancer , 2005, Oncogene.

[4]  J. Tchinda,et al.  Recurrent Fusion of TMPRSS2 and ETS Transcription Factor Genes in Prostate Cancer , 2005, Science.

[5]  A. Korshunov,et al.  Clinical utility of fluorescence in situ hybridization (FISH) in nonbrainstem glioblastomas of childhood , 2005, Modern Pathology.

[6]  Jason A. Koutcher,et al.  Crucial role of p53-dependent cellular senescence in suppression of Pten-deficient tumorigenesis , 2005, Nature.

[7]  D. Gandara,et al.  The AKT inhibitor perifosine in biochemically recurrent, hormone-sensitive prostate cancer (HSPC): A phase II California Cancer Consortium trial , 2005 .

[8]  I. Tannock,et al.  Effects of the mammalian target of rapamycin inhibitor CCI-779 used alone or with chemotherapy on human prostate cancer cells and xenografts. , 2005, Cancer research.

[9]  M. Mareel,et al.  Implication of the MAGI‐1b/PTEN signalosome in stabilization of adherens junctions and suppression of invasiveness , 2005, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[10]  Chawnshang Chang,et al.  Regulation of androgen receptor signaling by PTEN (phosphatase and tensin homolog deleted on chromosome 10) tumor suppressor through distinct mechanisms in prostate cancer cells. , 2004, Molecular endocrinology.

[11]  Shunyou Wang,et al.  PTENless means more. , 2004, Developmental biology.

[12]  S. Gygi,et al.  SKAR Is a Specific Target of S6 Kinase 1 in Cell Growth Control , 2004, Current Biology.

[13]  William R Sellers,et al.  The biology and clinical relevance of the PTEN tumor suppressor pathway. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  K. H. Gulkesen,et al.  The assessment of PTEN tumor suppressor gene in combination with Gleason scoring and serum PSA to evaluate progression of prostate carcinoma. , 2004, Urologic oncology.

[15]  Y. Sakurai,et al.  Abnormalities in chromosome 17 and p53 in lung carcinoma cells detected by fluorescence in situ hybridization , 2004, Pathology international.

[16]  K. Porkka,et al.  Molecular mechanisms of prostate cancer. , 2004, European urology.

[17]  T. Golub,et al.  mTOR inhibition reverses Akt-dependent prostate intraepithelial neoplasia through regulation of apoptotic and HIF-1-dependent pathways , 2004, Nature Medicine.

[18]  K. Failing,et al.  Expression of PTEN in malignant and non‐malignant human prostate tissues: comparison with p27 protein expression , 2004, The Journal of pathology.

[19]  Yidong Chen,et al.  High-resolution analysis of gene copy number alterations in human prostate cancer using CGH on cDNA microarrays: impact of copy number on gene expression. , 2004, Neoplasia.

[20]  H. Zentgraf,et al.  Reduction of PTEN and p27kip1 expression correlates with tumor grade in prostate cancer. Analysis in radical prostatectomy specimens and needle biopsies , 2004, Virchows Archiv.

[21]  R. Parsons.  Human cancer, PTEN and the PI-3 kinase pathway. , 2004, Seminars in cell & developmental biology.

[22]  D. Pinkel,et al.  Evaluation of genetic patterns in different tumor areas of intermediate‐grade prostatic adenocarcinomas by high‐resolution genomic array analysis , 2004, Genes, chromosomes & cancer.

[23]  Theodore L DeWeese,et al.  Pathological and molecular mechanisms of prostate carcinogenesis: Implications for diagnosis, detection, prevention, and treatment , 2004, Journal of cellular biochemistry.

[24]  T. Visakorpi,et al.  Molecular genetics of prostate cancer. , 2003, Annals of medicine.

[25]  P. Pandolfi,et al.  Pten Dose Dictates Cancer Progression in the Prostate , 2003, PLoS biology.

[26]  Cheng Li,et al.  Genome-wide loss of heterozygosity analysis from laser capture microdissected prostate cancer using single nucleotide polymorphic allele (SNP) arrays and a novel bioinformatics platform dChipSNP. , 2003, Cancer research.

[27]  O. Halvorsen,et al.  Combined loss of PTEN and p27 expression is associated with tumor cell proliferation by Ki-67 and increased risk of recurrent disease in localized prostate cancer. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[28]  Henrik Grönberg,et al.  Prostate cancer epidemiology , 2003, The Lancet.

[29]  T. Shuin,et al.  Detection of genetic alterations in advanced prostate cancer by comparative genomic hybridization. , 2002, Cancer genetics and cytogenetics.

[30]  C. Sawyers,et al.  The phosphatidylinositol 3-Kinase–AKT pathway in human cancer , 2002, Nature Reviews Cancer.

[31]  D. Woods,et al.  Phosphorylation of HDM2 by Akt , 2002, Oncogene.

[32]  M. Jewett,et al.  p53 Alteration and Chromosomal Instability in Prostatic High-Grade Intraepithelial Neoplasia and Concurrent Carcinoma: Analysis by Immunohistochemistry, Interphase In Situ Hybridization, and Sequencing of Laser-Captured Microdissected Specimens , 2001, Modern Pathology.

[33]  M. Ittmann,et al.  Haploinsufficiency of the Pten tumor suppressor gene promotes prostate cancer progression , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[34]  P. Pandolfi,et al.  Pten and p27KIP1 cooperate in prostate cancer tumor suppression in the mouse , 2001, Nature Genetics.

[35]  H. Frierson,et al.  Mutations of PTEN/MMAC1 in primary prostate cancers from Chinese patients. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[36]  Tapio Visakorpi,et al.  Molecular genetics of prostate cancer , 2001, Urology.

[37]  H. Höfler,et al.  Chromosomal changes during development and progression of prostate adenocarcinomas , 2001, British Journal of Cancer.

[38]  M. Müller,et al.  PTEN/MMAC1 mutations in prostate cancer , 2000, Prostate Cancer and Prostatic Diseases.

[39]  M. Skolnick,et al.  Microdissection, DOP-PCR, and comparative genomic hybridization of paraffin-embedded familial prostate cancers. , 2000, Cancer genetics and cytogenetics.

[40]  R. Vessella,et al.  Increased AKT Activity Contributes to Prostate Cancer Progression by Dramatically Accelerating Prostate Tumor Growth and Diminishing p27Kip1 Expression* , 2000, The Journal of Biological Chemistry.

[41]  M. Loda,et al.  Loss of PTEN expression in paraffin-embedded primary prostate cancer correlates with high Gleason score and advanced stage. , 1999, Cancer research.

[42]  V. Yong,et al.  PTEN/MMAC1/TEP1 in signal transduction and tumorigenesis. , 1999, European journal of biochemistry.

[43]  C. Bartoli,et al.  c-erbB2/neu gene and chromosome 17 analysis in breast cancer by FISH on archival cytological fine-needle aspirates , 1999, British Journal of Cancer.

[44]  M. Greenberg,et al.  Akt Promotes Cell Survival by Phosphorylating and Inhibiting a Forkhead Transcription Factor , 1999, Cell.

[45]  W. Sellers,et al.  Regulation of G1 progression by the PTEN tumor suppressor protein is linked to inhibition of the phosphatidylinositol 3-kinase/Akt pathway. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[46]  P. Rennie,et al.  Epigenetic Mechanisms for Progression of Prostate Cancer , 1998, Cancer and Metastasis Reviews.

[47]  A. Horii,et al.  Infrequent genetic alterations of the PTEN gene in Japanese patients with sporadic prostate cancer , 1998, Journal of Human Genetics.

[48]  John Calvin Reed,et al.  Regulation of cell death protease caspase-9 by phosphorylation. , 1998, Science.

[49]  J. A. Hamilton,et al.  Mutation and expression analysis of the putative prostate tumour-suppressor gene PTEN. , 1998, British Journal of Cancer.

[50]  H. Frierson,et al.  PTEN/MMAC1 is infrequently mutated in pT2 and pT3 carcinomas of the prostate , 1998, Oncogene.

[51]  D. Bostwick,et al.  Determination of gene and chromosome dosage in prostatic intraepithelial neoplasia and carcinoma. , 1998, Analytical and quantitative cytology and histology.

[52]  Carlos Cordon-Cardo,et al.  Pten is essential for embryonic development and tumour suppression , 1998, Nature Genetics.

[53]  O. Cussenot,et al.  PTEN/MMAC1/TEP1 involvement in primary prostate cancers , 1998, Oncogene.

[54]  R. Vessella,et al.  Inactivation of the tumor suppressor PTEN/MMAC1 in advanced human prostate cancer through loss of expression. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[55]  H. Feilotter,et al.  Analysis of PTEN and the 10q23 region in primary prostate carcinomas , 1998, Oncogene.

[56]  M. Ittmann,et al.  Homozygous deletion of the PTEN tumor suppressor gene in a subset of prostate adenocarcinomas. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.

[57]  W. Isaacs,et al.  Interfocal heterogeneity of PTEN/MMAC1 gene alterations in multiple metastatic prostate cancer tissues. , 1998, Cancer research.

[58]  J. Herman,et al.  Frequent inactivation of PTEN/MMAC1 in primary prostate cancer. , 1997, Cancer research.

[59]  S. R. Datta,et al.  Akt Phosphorylation of BAD Couples Survival Signals to the Cell-Intrinsic Death Machinery , 1997, Cell.

[60]  Jorma Isola,et al.  In vivo amplification of the androgen receptor gene and progression of human prostate cancer , 1995, Nature Genetics.

[61]  H. Grossman,et al.  PTEN gene therapy induces growth inhibition and increases efficacy of chemotherapy in prostate cancer. , 2005, Cancer detection and prevention.

[62]  K. Marumo,et al.  Inhibition of Wnt signaling downregulates Akt activity and induces chemosensitivity in PTEN‐mutated prostate cancer cells , 2005, The Prostate.

[63]  A. Jemal,et al.  Cancer Statistics, 2004 , 2004, CA: a cancer journal for clinicians.

[64]  Jin-Tang Dong.  Chromosomal Deletions and Tumor Suppressor Genes in Prostate Cancer , 2004, Cancer and Metastasis Reviews.

[65]  Taylor Murray,et al.  Cancer statistics, 2000 , 2000, CA: a cancer journal for clinicians.

[66]  W. Isaacs,et al.  For Personal Use. Only Reproduce with Permission from the Lancet Publishing Group. Pathological and Molecular Aspects of Prostate Cancer Prostate Cancer Ii , 2022 .